Introduction: Use of tranexamic acid (TXA) in trauma has been the subject of growing interest by researchers and health professionals. However, there are still several open questions regarding its use. In some aspects medical literature is controversial. The points of disagreement among experts include questions such as: Which patients should receive TXA in trauma? Should treatment be performed...

You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality Life and Shared Decision Making III (MP23)1 Sep 2021MP23-08 CYSTOSCOPIC INJECTION OF TRANEXAMIC ACID TO CONTROL REFRACTORY AND LIFE-THREATENING HEMATURIA: A NEW OPTION CONSIDER Brian Le, Katharine Tippins, Marissa Falkiewicz LeBrian Le More articles by this author , TippinsKatharine Tippins FalkiewiczMarissa V...

BACKGROUND This meta-analysis aimed to evaluate the efficiency and safety of combined intravenous and topical methods of application versus single intravenous of tranexamic acid in primary total knee and hip arthroplasty. METHODS A systematic search was carried out in MEDLINE (from 1966 to 25 September 2016), PubMed (from 1966 to 25 September 2016), Embase (from 1980 to 25 September 2016), Sc...

Background: Geriatric hip fracture patients frequently suffer femoral neck injuries. The advantage of using TXA topically over the IV route is that maximum concentration drug attained at wound/surgical site with minimal systemic side effects and also it easy to administer locally. Aim current study was fragmented necks femur can be treated Tranexamic acid reduce postoperative blood loss. Method...

Patients suffering from acute myeloid leukemia (AML) carry a high risk of serious bleeding complications due to severe thrombocytopenia for long periods time during treatment. Prior prophylactic platelet transfusion becoming the standard care, intracranial was major contributor death in AML patients. However, despite transfusions, up 79% patients with experience clinically significant Antifibri...

Tranexamic acid (TXA), an antifibrinolytic agent, has recently been investigated as a potentially useful drug for both prevention and treatment of Primary Postpartum Hemorrhage (PPH). This article highlights the continuing evolvement of this antifibrinolytic medication in the broad field of anesthesiology, and more specifically, obstetric anesthesiology, focusing on three important aspects of T...

BACKGROUND This study aims to compare the effectiveness and safety of topical versus intravenous tranexamic acid (TXA) in reducing blood loss in primary total knee arthroplasty (TKA). METHODS PubMed, Embase, the Cochrane Library, Web of Science, Chinese Biomedicine Literature (CBM), Wanfang Database and China National Knowledge Infrastructure (CNKI), and Google Scholar were searched for rando...

Background Studies on the use of tranexamic acid (TXA) to improve clinical outcomes after joint arthroplasty have reported contrasting results between intravenous (IV) TXA alone and combined IV and intraarticular (IA) administration. We compared the effectiveness of the 2 methods in providing higher postoperative hemoglobin (Hb) levels in patients undergoing primary total knee arthroplasty (TKA...

Pulmonary hemorrhage (PH) is rarely seen in neonates and generally occurs based on the pathological process as perinatal asphyxia. Additionally, hypothermia treatment can be associated with thrombocytopenia and hemorrhage in term infants. Generally, PH is severe and persistant hemorrhage can related to neonatal mortality. Sometimes, supportive therapies such as positive-end expiratory pressure ...

Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that inhibits fibrinolysis by blocking the interaction of plasminogen with the lysine residues of fibrin. Historically, TXA is commonly used for reduction of blood loss in perioperative situations, while recently it has attracted attention for clinical use in the trauma field. In 2010, the Clinical Randomization of an Anti...